Literature DB >> 8327128

Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS.

G A Suarez1, J J Kelly.   

Abstract

We evaluated the clinical characteristics and electromyographic features of 39 patients with monoclonal gammopathy of undetermined significance (MGUS) and neuropathy. Twenty-three patients had a monoclonal IgM protein, 13 had an IgG, and three had an IgA. In 15 patients of the IgM group, the M protein reacted with myelin-associated glycoprotein (MAG). Comparing IgM-MGUS and IgG-MGUS neuropathies, we found the following differences: (1) There was a statistically significant higher frequency of sensory loss in the IgM group. (2) Nine attributes of nerve conduction abnormality were statistically worse in the IgM group, with slowing of conduction velocities and prolonged distal latencies. (3) The frequency of monoclonal IgM was overrepresented in the MGUS neuropathy group. In general, the clinical and electrophysiologic features of the IgM-MGUS MAG-reactive group were not significantly different than the MAG-nonreactive group. Our cases are similar to those previously reported and suggest that monoclonal IgM-MGUS should be separated conceptually from monoclonal IgG neuropathies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327128     DOI: 10.1212/wnl.43.7.1304

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Immunological mechanisms in paraneoplastic peripheral neuropathy.

Authors:  J C Antoine
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  [Polyneuropathies in monoclonal gammopathy of undetermined significance: initial manifestation of a lymphoma].

Authors:  C Drees; M Grond; B Szelies; M Dietlein; B Salzberger; V Diehl; W D Heiss
Journal:  Med Klin (Munich)       Date:  1997-02-15

Review 3.  Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Authors:  Hafsa M Chaudhry; Michelle L Mauermann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

4.  Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Authors:  T Maisonobe; B Chassande; M Vérin; M Jouni; J M Léger; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

5.  Axonal neuropathy associated with monoclonal gammopathy of undetermined significance.

Authors:  K C Gorson; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

6.  The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.

Authors:  Christopher J Klein; Joon-Shik Moon; Michelle L Mauermann; Steven R Zeldenrust; Yanhong Wu; Angela Dispenzieri; Peter J Dyck
Journal:  Can J Neurol Sci       Date:  2011-03       Impact factor: 2.104

Review 7.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Analyzing Relationship Between Monoclonal Gammopathy of Undetermined Significance (MGUS) with Different Types of Neuropathy: An Observational Study.

Authors:  Shahzaib Nabi; Pushpinderdeep Kahlon; Farshid Bozorgnia; Adeel Arshad; Akmam Saleem; Philip Kuriakose
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-28       Impact factor: 0.900

Review 9.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

Review 10.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.